Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures

Fig. 2

Inhibition of inflammation-related mRNAs and iNOS mRNA production under both LPS and kainic acid treatment by minocycline, everolimus, and rapamycin in BV2 cell line. Lipopolysaccharide (LPS) increased IL-1β, NLRP3, mTOR, and iNOS mRNA production (ad), and kainic acid (KA) increased only mTOR and iNOS mRNA production (c, d). a Minocyclin, rapamycin, and everolimus had no effect on IL-1β mRNA production under both LPS and KA treatment. b Rapamycin increased NLRP3 mRNA production under KA treatment significantly, but not under LPS treatment. Minocyclin and everolimus had no effect on NLRP3 mRNA production. c Everolimus decreased mTOR mRNA production under both LPS and KA treatment, while minocyclin and rapamycin had no effect on it. d Minocyclin, rapamycin, and everolimus all attenuated iNOS mRNA production under both LPS and KA treatment. n = 4 for each group. ***p < 0.001; **p < 0.01; *p < 0.05; m: p < 0.1, compared with the control group (Ctl). ### p < 0.001; ## p < 0.01; # p < 0.05, compared with the LPS and KA groups. Data are presented as mean ± SEM. Ctl control, E everolimus, KA/K kainic acid, LPS/L lipopolysaccharide, M minocycline, R rapamycin

Back to article page